Arbutus Biopharma terminated its 2025 RSV Agreement with Genevant via a Termination Agreement dated Jul 15, 2026. The arrangement, which addressed allocation of damages or settlement proceeds tied to Moderna’s mRESVIA vaccine, is fully ended, with Genevant to pay Arbutus a $1.0 million termination fee within ten business days. The move follows a broader settlement with Moderna that did not specifically allocate proceeds to mRESVIA.
Agreement details:
- Agreement terminated: RSV Agreement on mRESVIA-related damages allocation
- Counterparty: Genevant Sciences
- Termination date: Jul 15 2026
- Termination type: mutual
- Exit fees / payments: $1.0 million
- Reason: Settlement lacked mRESVIA allocation; parties ended allocation arrangement
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.